drugset / Trial / NCT06249256
An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of fast autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies in patients with solid tumors.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BZT2312 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | BZT2312 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | BZT2312 | Cell therapy | 5e+06 cells/kg | Intravenous |